A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil
← catalyst calendarNCT06008353 · readout in 11 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
60estimated
Sites
5
Country
Brazil
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-18 | actual | When the study began enrolling |
| Primary completion | 2026-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-12-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Extensive-stage Small-cell Lung Cancer
Intervention
- Other: Observational study
Primary outcomes
what the primary-completion date above is the date OFDemographic Characteristics of the Cohort
measured Baseline.
Clinical Characteristics of the Cohort
measured Baseline.
Comparison of Demographic and Clinical Characteristics between Recurrent and Newly Diagnosed CPPC-EE Patients
measured During the cohort follow-up, an average of 24 months, starting from diagnosis.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed